article thumbnail

NHS England launches country-wide cancer vaccine trials

Drug Discovery World

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccine 147
article thumbnail

“Game-changing” personalised cancer vaccine enters UK clinical trials   

Drug Discovery World

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. The vaccines are personalised to each patient after a tumour sample is removed during surgery and then analysed using DNA sequencing. in the combination arm and 62.2%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vaccines and various response rates

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial?

Vaccine 147
article thumbnail

Cancer vaccine shows sustained improvement in survival rates

Drug Discovery World

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” months after initial treatment.

Vaccine 147
article thumbnail

Collaborative study aims to improve flu and Covid-19 vaccine design

Drug Discovery World

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most vulnerable.

Vaccine 130
article thumbnail

LDL cholesterol vaccine ‘could be a game-changer’

Drug Discovery World

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. We’re excited to get this first-in-human trial of VXX-401 started.

Vaccine 130
article thumbnail

New clinical trial facility opens in Liverpool

Drug Discovery World

The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR). The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities.